Pediatric non-Hodgkin lymphoma

O’Leary M, Sheaffer J, Keller F, et al.: Lymphomas and reticuloendothelial neoplasms. In Cancer Epidemiology in Older Children and Young Adults 15–29 Years of Age, Including SEER Incidence and Survival: 1975–2000. Edited by Bleyer A, O’Leary M, Barr R, et al.: NIH pub. No. 06-5767: Bethesda, MD: National Cancer Institute; 2006:25–38. Sandlund JT, Downing JR, Crist WM: Non-Hodgkin’s lymphoma in childhood. N Engl J Med 1996, 334:1238–1248. Gross TG, Shiramizu B: Lymphoproliferative disorders related to immunodeficiencies. In Pediatric Lymphomas. Edited by Weinstein HJ, Hudson MM, Link MP. New York: Springer-Verlag; 2007:233–258. Seidemann K, Tiemann M, Henze G, et al.: Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: analysis of 19 patients from the BFM trials. Med Pediatr Oncol 1999, 33:536–544. Gross TG, Bucuvalas JC, Park JR, et al.: Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005, 23:6481–6488. Murphy SB, Fairclough DL, Hutchison RE, et al.: Non-Hodgkin’s lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 1989, 7:186–193. Sabesan V, Cairo MS, Lones MA, et al.: Assessment of minimal residual disease in childhood non-Hodgkin lymphoma by polymerase chain reaction using patient-specific primers. J Pediatr Hematol Oncol 2003, 25:109–113. Campana D, Coustan-Smith E, Sandlund JT, Abromowitch M: A novel approach for staging and minimal residual disease detection in patients with T-cell lymphoblastic lymphoma: a Children’s Oncology Group study. Ann Oncol 2005, 16(Suppl 5):62. Burkhardt B, Zimmermann M, Oschlies I, et al.: The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005, 131:39–49. Harris NL, Jaffe ES, Diebold J, et al.: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835–3849. Oschlies I, Klapper W, Zimmermann M, et al.: Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood 2006, 107:4047–4052. Miles RR, Raphael M, McCarthy K, et al.: Expression of BCL2 and C-MYC in pediatric diffuse large B-cell lymphoma. Pediatr Blood Cancer 2006, 46:860. Dave SS, Fu K, Wright GW, et al.: Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 2006, 354:2431–2442. Seidemann K, Tiemann M, Lauterbach I, et al.: Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group. J Clin Oncol 2003, 2:1782–1789. Patte C, Auperin A, Gerard M, et al.: Results of randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce tretment for early responding patients. Blood 2007, 109:2773–2780. Rosenwald A, Wright G, Leroy K, et al.: Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of e large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003, 198:851–862. Cairo MS, Gerard M, Sposto R, et al.: Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007, 109:2736–2743. Woessmann W, Seidemann K, Mann G, et al.: The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005, 105:948–958. Link MP, Shuster JJ, Donaldson SS, et al.: Treatment of children and young adults with early-stage non-Hodgkin’s lymphoma. N Engl J Med 1997, 337:1259–1266. Reiter A, Schrappe M, Tiemann M, et al.: Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 1999, 94:3294–3306. Patte C, Auperin A, Michon J, et al.: The Société Française d’Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001, 97:3370–3379. Pfeundschuh M Trumper L, Osterborg A, et al.: CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379–391. Mounier N, Briere J, Gisselbrecht C, et al.: Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma. (DL-BCL). Blood 2003, 101:4279–4284. Thomas DA, Faderl S, O’Brien S, et al.: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006, 106:1569–1580. Reatz EA, Perkins SL, Bhojwani D, et al.: Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer 2006, 47:130–140. Anderson JR, Jenkin RD, Wilson JF, et al.: Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin’s lymphoma: a report of CCG-551 from the Children’s Cancer Group. J Clin Oncol 1993, 11:1024–1032. Burkhardt B, Woessmann W, Zimmermann M, et al.: Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 2006, 24:491–499. Asselin BL, Shuster J, Amylon M, et al.: Improved event-free survival (EFS) with high-dose methotrexate (HDM) in T-cell lymphoblastic leukemia (T-ALL) and advanced lymphoblastic lymphoma (T-NHL): a Pediatric Oncology Group (POG) study. Proc ASCO 2001, 20:367. Leung W, Sandlund JT, Hudson MM, et al.: Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer 2001, 92:1959–1966. Reiter A, Schrappe M, Ludwig WD, et al.: Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000, 95:416–421. Hoelzer D, Gokbuget N, Digel W, et al.: Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002, 99:4379–4385. Ferrando AA, Neuberg DS, Staunton J, et al.: Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002, 1:75–87. Coustan-Smith E, Sancho J, Hancock ML, et al.: Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002, 100:2399–2402. Duyster J, Bai RY, Morris SW: Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 2001, 20:5623–5637. Seidemann K, Tiemann M, Schrappe M, et al.: Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 2001, 97:3699–3706. Kumar S, Pittaluga S, Raffeld M, et al.: Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature. Pediatr Dev Pathol 2005, 8:52–60. Hinshaw M, Trowers AB, Kodish E, et al.: Three children with CD30 cutaneous anaplastic large cell lymphomas bearing the t(2;5)(p23;q35) translocation. Pediatr Dermatol 2004, 21:212–217. Laver JH, Kraveka JM, Hutchison RE, et al.: Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol 2005, 23:541–547. Laver JH, Mahmoud H, Pick TE, et al.: Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin’s lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma 2001, 42:399–405. Falini B, Pileri S, Zinzani PL, et al.: ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999, 93:2697–2706. Brugières L, Quartier P, Le Deley MC, et al.: Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children—a report from the French Society of Pediatric Oncology. Ann Oncol 2000, 11:53–58. Bartlett NL, Bernstein SH, Leonard JP, et al.: Safety, antitumor activity and pharmacokinetics of six weekly doses of SGN-30 (anti-CD30) monoclonal antibody in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2003, 102:647. Sausville EA, Arbuck SG, Messmann R, et al.: Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001, 19:2319–2333. Attarbaschi A, Dworzak M, Steiner M, et al.: Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group. Pediatr Blood Cancer 2005, 44:70–76. Lorsbach RB, Shay-Seymore D, Moore J, et al.: Clinicopathologic analysis of follicular lymphoma occurring in children. Blood 2002, 99:1959–1964. Abla O, Weitzman S: Primary central nervous system lymphoma in children. Neurosurg Focus 2006, 21:1–8. Claviez A, Meyer U, Dominick C, et al.: MALT lymphoma in children: a report from the NHL-BFM study group. Pediatr Blood Cancer 2006, 47:210–214. Rosh JR, Gross T, Mamula P, et al.: Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis 2007, 13:1024–1030. Carbone PP, Kaplan HS, Musshoff K, et al.: Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 1971, 31:1860–1861.